Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

Core Insights - Pliant Therapeutics presented positive clinical data for bexotegrast, an oral inhibitor targeting αvβ6 and αvβ1 integrins, at The Liver Meeting® 2024, indicating its potential in treating primary sclerosing cholangitis (PSC) [2][3] - The INTEGRIS-PSC trial results showed that bexotegrast was well tolerated and demonstrated antifibrotic and anti-cholestatic activity, with improvements in liver stiffness, Enhanced Liver Fibrosis (ELF) scores, and liver biochemistry [3] - A separate study identified novel inflammatory serum and urinary protein biomarkers for PSC, suggesting potential for improved diagnostics and progression prediction [4] Company Overview - Pliant Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases, with bexotegrast as its lead product candidate [6] - Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the FDA for both idiopathic pulmonary fibrosis (IPF) and PSC, and similar designations from the European Medicines Agency [6] - The company is also conducting a Phase 1 study for PLN-101095, a small molecule targeting solid tumors, and has regulatory clearance for a Phase 1 study of PLN-101325, aimed at muscular dystrophies [6]